NCT02513199View on ClinicalTrials.gov

Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

January 1, 2022

Study Completion Date

January 1, 2022

Conditions
Hepatocellular Carcinoma
Interventions
RADIATION

SBRT

Radiation is to be delivered to 30-45 Gy in 5 fractions. 40 Gy in 5 fractions will be utilized, unless dose constraints preclude it. Treatment will optimally be delivered every other day with no more than 3 fractions per week. The ideal treatment team will be less than 15 total days.

DRUG

TACE

two sessions of standard TACE with ethiodol separated by a 4-week interval.

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT02513199 - Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter